We set the week’s question on Monday: can anyone catch Lilly in obesity? Friday’s answer is the clearest one yet.
Lilly reported $16.2 billion in second quarter revenue, up 25% year over year. Zepbound alone generated $3.8 billion, up 78%. Foundayo uptake is strong. Retatrutide’s Q1 2027 filing with weight loss above 20% at 80 weeks is confirmed. And the company walked analysts through how the GLP 1 franchise is funding the acquisitions while the acquisitions build the next decade.
That last point is the one worth sitting with. Lilly is not just posting big revenue numbers. It is using those numbers to fund the most aggressive pipeline buildout in pharmaceutical history—fifteen deals, eleven company acquisitions, ten therapeutic areas, eight modalities. And the revenue keeps growing fast enough to fund the next round of deals without slowing down. The growth validates the strategy, and the strategy generates more growth. That is how a company pulls away from the field.
On the same day, AstraZeneca and BMS both denied merger talks. Moderna got the mRNA flu vaccine approved—a genuine milestone. Novo missed on obesity and confirmed a CagriSema delay. And the FDA approved the first drug with an AI designed component.
Lilly’s Quarter: The Numbers That Fund the Future
What Happened: Lilly reported Q2 revenue of $16.2 billion, up 25% year over year, driven by Zepbound ($3.8 billion, +78%) and strong Foundayo uptake. The company confirmed a Q1 2027 regulatory filing for retatrutide.
The Revenue Is the Strategy
Every deal Lilly has made this year—Kelonia ($3.2 billion, in vivo CAR T), Orna (circular RNA CAR T), CrossBridge (dual payload ADC), Profluent ($2.25 billion, AI gene editing), AtaiBeckley ($3.8 billion, psychedelics), and the rest—was funded by a franchise that just grew 25% in a quarter and shows no signs of decelerating.
Zepbound at $3.8 billion in a single quarter is a trajectory that puts it on pace for a $15 billion plus annualized run rate, and it is still expanding into new indications, new geographies, and the Medicare Bridge population. Foundayo’s strong uptake confirms that the oral convenience tier is adding patients who want the GLP 1 benefit without the needle. Retatrutide, with three positive pivotal trials and a Q1 2027 filing confirmed, adds the highest efficacy tier to the portfolio.
The three tier framework we described throughout the spring is now producing measurable results:
Foundayo (oral, approximately 12% weight loss): convenience tier, strong early uptake, T2D filing imminent.
Zepbound (injectable, approximately 22% weight loss): established franchise, $3.8 billion quarterly revenue, growing 78%.
Retatrutide (injectable, approximately 28% weight loss): maximum efficacy tier, three pivotal wins, filing Q1 2027, 2027 launch projected.
No competitor has anything resembling this portfolio breadth or this revenue growth. The GLP 1 cash flow funds the deal spree. The deal spree builds the next decade. And the revenue keeps growing fast enough that the acquisitions look like a rounding error on the income statement rather than a financial strain. That is the position every pharmaceutical company wants and almost none achieve.
What It Means for the Week’s Question
We asked Monday whether the challengers—Novo defending, Roche refocusing, Arrowhead teasing early signals, Pfizer rebuilding—can close the gap with Lilly. The earnings print answers clearly: not soon. Lilly is pulling away on revenue, on pipeline breadth, on filing timelines, and on the financial capacity to keep acquiring. The gap is not just efficacy. It is the entire system that efficacy funds.
Our Pro brief models the franchise trajectory and what it means for every company trying to compete. [Details below.]
AstraZeneca and BMS Both Denied the Merger Report
What Happened: Both AstraZeneca and BMS denied engaging in merger talks, responding to the Financial Times report from Monday that said the companies had explored combining.
What a Denial Means and What It Does Not
The FT reported that AstraZeneca has “explored the idea of combining” with BMS. Both companies denied the characterization. The language matters: there is a wide spectrum between informal exploration of strategic options (which large companies do routinely) and formal merger negotiations (which involve board mandates, legal engagement, and due diligence). The FT report and the denials can both be true if the contacts were exploratory rather than negotiated.
What the denials tell you: the talks apparently did not advance far enough for either company to characterize them as negotiations, or at least not far enough that either wants to confirm them publicly. That is consistent with our read throughout the week—that the report was more useful as a signal of the consolidation pressure at the top of the industry than as a prediction of a specific deal.
What the denials do not tell you: whether the idea is permanently off the table. Companies deny exploration all the time, even when the exploration was real, because acknowledging it creates market expectations and regulatory complications. Whether AstraZeneca and BMS circle back depends on how the next twelve months unfold for both—the pipeline readouts, the patent cliff timelines, and the competitive environment that is pushing the largest companies to consider options they would not have contemplated five years ago.
The signal we have carried all week holds: the consolidation pressure at the top of the industry is real and increasing, whether or not this specific combination happens.
The mRNA Flu Vaccine Is Approved, and Moderna Just Changed Its Future
What Happened: The FDA approved Moderna’s mRNA seasonal influenza vaccine, making it the first mRNA based flu shot on the U.S. market.
Why This Matters More Than Any Single Product Approval
We have tracked this from the positive FDA briefing documents in June, through the advisory committee endorsement, to today’s approval. At each step we said the same thing: this is the most important product approval Moderna has achieved since the original COVID vaccine, because it validates the mRNA platform for routine, annual, commercial use rather than emergency pandemic response.
That distinction is existential for Moderna. COVID vaccine demand has declined sharply from pandemic peaks. The company needs to demonstrate that its mRNA platform can produce competitive products in established markets, not just respond to a once in a generation emergency. An approved seasonal flu vaccine does exactly that.
What the Approval Changes
For Moderna: The company transforms from a pandemic vaccine maker into a platform vaccine company. An mRNA flu shot that competes with established products from Sanofi (Fluzone), Seqirus (Flucelvax, Fluad), and GSK (Fluarix) generates recurring annual revenue and proves the platform works in a competitive, routine market. Combination vaccines (flu plus COVID, flu plus RSV) become possible now that both the flu and COVID vaccines are individually validated.
For the flu market: The mRNA manufacturing advantage—weeks to produce rather than months for egg based vaccines—allows better strain matching. When circulating flu strains drift late in the season, an mRNA vaccine can adapt faster than traditional approaches, potentially improving effectiveness in seasons where strain mismatch has historically been a problem.
For physicians and patients: A new option in the annual flu vaccination landscape. The mRNA flu vaccine enters alongside established alternatives, giving physicians another choice and giving patients a product made with the same technology that powered the COVID vaccine many of them have already received.
For the broader mRNA field: The approval demonstrates that mRNA technology works beyond pandemic applications. If mRNA can make a competitive flu vaccine, the same manufacturing infrastructure can produce vaccines for RSV, CMV, and other respiratory pathogens, as well as the combination products that reduce the number of shots patients need each season.
Novo Missed on Obesity and Confirmed the CagriSema Delay
What Happened: Novo Nordisk’s second quarter obesity franchise missed analyst estimates, and the company confirmed a delay in CagriSema Phase 3 data. Shares fell further.
The Week’s Verdict on Novo Could Not Be Clearer
We tracked the contrast between Novo and Lilly all week, and the earnings prints landed exactly where the clinical and corporate trajectories predicted.
Lilly: $16.2 billion revenue, +25%. Zepbound $3.8 billion, +78%. Retatrutide filing confirmed Q1 2027. Three positive pivotal trials. Fifteen deals funded by the cash flow.
Novo: Obesity franchise missed estimates. CagriSema Phase 3 data delayed again. Ziltivekimab cardiovascular trial failed earlier this week (shares down 9%). Shareholder lawsuit over CagriSema protocol changes. Advertising lawsuit against Lilly escalated to an injunction request.
The competitive gap between the two companies has widened measurably over the past seven days. Lilly is executing across every front—clinical data, regulatory filings, commercial performance, and dealmaking—while Novo is absorbing misses across its pipeline, its commercial performance, and its legal docket.
Novo remains a formidable company with deep commercial infrastructure, global physician relationships, and the franchise it created with semaglutide. It is not going away. But the narrative has shifted decisively from “two giants competing on equal terms” to “one company pulling ahead while the other works to stabilize.” The CagriSema delay is particularly damaging because it was meant to be the mechanism that closed the efficacy gap with tirzepatide. Delaying that data extends the period where Novo cannot answer Lilly’s strongest clinical argument.
The FDA Approved the First Drug With an AI Designed Component
What Happened: The FDA approved a cancer drug that includes a component designed using artificial intelligence, marking the first time an AI designed element has reached an approved medicine.
A Milestone, Not a Revolution—Yet
We have tracked AI drug discovery deals all year. Isomorphic Labs ($2.7 billion). Insilico/SK ($2.5 billion). Lilly/Profluent ($2.25 billion). Chai Discovery ($400 million at $3.8 billion valuation). The Anthropic pharma ecosystem. Alnylam/Inceptive for RNA. Insilico/Takeda. The capital flowing into AI drug discovery has been enormous.
What the field has lacked until today is an approved product. A drug that actually made it through clinical trials, regulatory review, and the FDA’s approval process with an AI designed component. That milestone is now achieved.
The practical significance should be kept in proportion. AI contributed a component of this drug, not the entire molecule. The clinical trials, the manufacturing, the regulatory submission, and the safety monitoring were all conducted through the same processes that every other drug follows. AI did not compress the development timeline to months or eliminate clinical failure—it contributed to the design of a piece of the medicine.
But the precedent matters. An approved drug with an AI designed component proves that AI generated chemistry can survive the full rigor of pharmaceutical development and regulatory scrutiny. It validates the technology not as a promise but as a demonstrated capability. And it opens the door for the next generation of AI designed drugs that are advancing through the pipeline right now.
Anthropic’s CEO tempering AI timeline expectations in early July now looks prescient rather than deflationary. The technology works. The approval proves it. But the timelines are measured in years, not months, and the contribution is incremental rather than revolutionary—at least for now. The companies that will capture the most value from AI in drug development are the ones using it as a tool that makes specific parts of the process faster and better, not the ones promising it will replace the process entirely.
Quick Hits
Biogen began Phase 3 enrollment for diranersen in Alzheimer’s, pushing forward with the anti tau program despite the missed Phase 2 primary endpoint. The unprecedented tau reduction we covered at the AAIC conference in July validated the science enough for Biogen to bet on a larger trial. Whether the Phase 3 confirms the biomarker promise with actual cognitive benefit is the defining question for Biogen’s neuroscience pivot.
Servier completed its $2.6 billion acquisition of Cellectis, the gene editing company focused on allogeneic CAR T cell therapies. The deal gives the French pharma company control of one of the leading off the shelf CAR T platforms, where cells are manufactured from healthy donors rather than from each individual patient. Allogeneic CAR T has the potential to dramatically reduce the manufacturing complexity and cost that limit autologous (patient derived) CAR T, though the clinical results have lagged behind the autologous programs that dominate the market today.
Vir Biotechnology announced layoffs, another addition to the ongoing but slowing biopharma workforce reduction trend. Vir has been narrowing its focus since COVID era revenue declined, and the cuts reflect the same prioritization pattern we have tracked across the sector: concentrate resources on the programs most likely to deliver, cut everything else.
Grail announced progress on its multi cancer early detection blood test, advancing the liquid biopsy technology that aims to detect cancers through a simple blood draw before symptoms appear. The technology, if validated across enough cancer types with sufficient sensitivity and specificity, could transform cancer screening from a series of organ specific tests (mammograms, colonoscopies, CT scans) into a single blood based platform.
Strategic Themes
1. Lilly’s Quarter Proved the Entire System Works
The GLP 1 franchise grew 25%. The growth funds fifteen acquisitions. The acquisitions build the next decade. And the franchise keeps accelerating. That loop—revenue funding deals, deals building pipeline, pipeline extending the franchise’s life—is what separates Lilly from every other company in the industry right now. It is not just that Lilly has the best drugs. It is that the best drugs generate the resources to ensure the company keeps having the best drugs. The gap is systemic, not just clinical.
2. The mRNA Flu Vaccine Transforms Moderna from a Pandemic Company into a Platform Company
COVID proved mRNA works in an emergency. The flu vaccine proves it works as a routine commercial product. That transformation changes Moderna’s entire valuation thesis, its competitive positioning against established vaccine makers, and the foundation for every combination respiratory product in its pipeline. This is the approval that the mRNA platform needed to demonstrate its commercial durability.
3. Novo’s Rough Week Made the Obesity Competition’s Direction Unmistakable
Ziltivekimab cardiovascular failure. Obesity sales miss. CagriSema delay confirmed. Shareholder lawsuit. Advertising litigation. Against Lilly’s $16.2 billion quarter with Zepbound growing 78% and retatrutide filing confirmed. The direction is clear: Lilly is pulling ahead, and the mechanisms that were supposed to close the gap (CagriSema for efficacy, ziltivekimab for cardiovascular diversification) are both delayed or failed. Novo will compete from strength for years—the semaglutide franchise is enormous and durable. But the battle for leadership has tilted decisively.
4. The First AI Designed Approved Drug Is a Milestone Worth Celebrating Without Overstating
An AI designed component in an approved medicine validates the technology through the most rigorous test available—full FDA review and approval. But it is a component, not a whole drug. The contribution is real and the precedent matters, but the revolution in drug development that AI promises is still measured in years of incremental improvement rather than in overnight transformation. The companies and investors with realistic timelines will capture the most value.
Frequently Asked Questions
How did Lilly’s quarter look?
$16.2 billion revenue, up 25% year over year. Zepbound $3.8 billion (+78%). Foundayo uptake strong. Retatrutide Q1 2027 filing confirmed. The GLP 1 franchise is funding the most aggressive acquisition program in pharma history while growing at a pace that shows no deceleration.
Did AstraZeneca and BMS deny the merger?
Both companies denied engaging in merger talks. The FT had reported they explored combining. The denials suggest the contacts did not advance to formal negotiations, but the consolidation pressure that prompted the exploration persists regardless of whether this specific deal happens.
Is the mRNA flu vaccine approved?
Yes. The FDA approved Moderna’s mRNA seasonal flu vaccine, the first on the U.S. market. It validates the mRNA platform for routine commercial use beyond COVID and transforms Moderna from a pandemic vaccine company into a platform vaccine company.
What happened with Novo?
The obesity franchise missed analyst estimates in Q2. CagriSema Phase 3 data were delayed again. This follows the ziltivekimab cardiovascular trial failure earlier this week. The competitive gap with Lilly has widened across clinical, commercial, and pipeline dimensions.
What is the first AI designed approved drug?
The FDA approved a cancer drug with a component designed using artificial intelligence, the first time AI designed chemistry has reached an approved medicine. The milestone validates the technology but the contribution was a component, not the entire drug, and the development followed standard clinical and regulatory processes.
What is Servier/Cellectis?
Servier completed its $2.6 billion acquisition of Cellectis, gaining one of the leading allogeneic (off the shelf) CAR T platforms. Allogeneic CAR T aims to reduce the manufacturing complexity of patient derived cell therapies.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Lilly’s System Is Self Reinforcing. We model how the GLP 1 revenue funds the acquisition program, how the acquisitions build the next decade’s pipeline, and why the loop that connects them makes Lilly’s lead structural rather than cyclical. The franchise trajectory at these growth rates makes the $70 billion projection look conservative.
Moderna’s mRNA Flu Approval Changes Everything for the Platform. We analyze the commercial path against Sanofi, Seqirus, and GSK, assess the manufacturing speed advantage for strain matching, and model what approval means for the combination respiratory vaccine pipeline that follows.
Novo’s Week Was a Turning Point. We compile the accumulating evidence that the competitive gap is widening, assess what CagriSema needs to show when the data eventually arrive, and evaluate whether Novo can stabilize its narrative before the gap becomes permanent.
Plus: AZ/BMS denial analysis, first AI approved drug implications, Biogen diranersen Phase 3, Servier/Cellectis gene editing, Grail liquid biopsy progress, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
